answered Oct 01, 2010 at 09:58AM
In trials, Tacrine has been found to be slightly helpful in the treatment of Alzheimer's disease, however, it is not preferable because it has a low oral bio-availability, and is thus not absorbed well. Therefore, it is no longer a first line drug in this disease. Patients are now prescribed other acetylcholinesterase inhibitors such as Rivastigmine (exelon) Donepezil (Aricept) and Galantamine (Razadyne). None of these drugs are terribly effective however (only appx 30% respond at all, and even then minimally). The drug does not improve current cognition, but can make the decline in cognition move slightly slower. However, the side effects of the medication are often worse than the decline in cognition that could be offset by the drugs, causing patients to become more agitated. The worst symptom, and most common is diarrhea and gastrointestinal distress.